Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Aytu Biopharma (AYTU) Income towards Parent Company: 2011-2025

Historic Income towards Parent Company for Aytu Biopharma (AYTU) over the last 15 years, with Jun 2025 value amounting to $620,000.

  • Aytu Biopharma's Income towards Parent Company rose 415.75% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 195.99%. This contributed to the annual value of $620,000 for FY2025, which is 118.65% up from last year.
  • According to the latest figures from FY2025, Aytu Biopharma's Income towards Parent Company is $620,000, which was up 118.65% from -$3.3 million recorded in FY2024.
  • Aytu Biopharma's 5-year Income towards Parent Company high stood at $620,000 for FY2025, and its period low was -$108.8 million during FY2022.
  • Over the past 3 years, Aytu Biopharma's median Income towards Parent Company value was -$3.3 million (recorded in 2024), while the average stood at -$6.6 million.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first crashed by 327.93% in 2021, then skyrocketed by 118.65% in 2025.
  • Aytu Biopharma's Income towards Parent Company (Yearly) stood at -$58.3 million in 2021, then slumped by 86.62% to -$108.8 million in 2022, then skyrocketed by 84.21% to -$17.2 million in 2023, then surged by 80.65% to -$3.3 million in 2024, then spiked by 118.65% to $620,000 in 2025.